Promoter choice influences alternative splicing and determines the balance of isoforms expressed from the mouse bcl-X gene

被引:60
作者
Pecci, A
Viegas, LR
Barañao, JL
Beato, M [1 ]
机构
[1] Inst Mol Biol & Tumorforsch, D-35033 Marburg, Germany
[2] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, RA-1428 Buenos Aires, DF, Argentina
[3] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina
关键词
D O I
10.1074/jbc.M008665200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Differential splicing from the bcl-X gene generates several isoforms with opposite effects on the apoptotic response. To explore the mechanism controlling the balance between the various isoforms, we have characterized the 5' region of the mouse bcl-X gene. We identified three new promoters in addition to the two previously described (Grillot, D. A, M., G.-G., Ekhterae, D., Duan, L., Inohara, N., Ohta, S., Seldin, M. F., and Nunez, G. (1997) J. Immunol. 158, 4750-4757). These five promoters (P1-P5) would give rise to at least five mRNAs with different 5'-untranslated region, all sharing the same translation initiation site. Except for the product of the most proximal promoter (P1), the other mRNAs are generated by alternative splicing of noncoding exons to a common acceptor site located in the first translated exon. Reverse transcriptase-polymerase chain reaction, primer extension, and RNase protection assays demonstrate a tissue-specific pattern of promoter usage. P1 and P2 are active in all tissues analyzed, whereas the other three promoter show tissue-specific activities. P3 is active in spleen, liver, and kidney, P4 is active in uterus and spleen, and P5 is active in spleen, liver, brain, and thymus, We present evidence suggesting that promoter selection influences the outcome of the splice process. Transcripts from P1 generate mainly the mRNA for the long isoform Bcl-X-L, whereas transcripts from P2 generate mRNAs for the isoforms Bcl-X-L, Bcl-X-S, and Bcl-X-gamma and transcripts from P3 yield mainly mRNAs for the isoform Bcl-X-gamma. Our results suggest a key role of promoter choice in determining alternative splicing and, thus, the balance of Bcl-X isoforms.
引用
收藏
页码:21062 / 21069
页数:8
相关论文
共 36 条
[11]  
FANG W, 1994, J IMMUNOL, V153, P4388
[12]   Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes [J].
Fujio, Y ;
Kunisada, K ;
Hirota, H ;
YamauchiTakihara, K ;
Kishimoto, T .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (12) :2898-2905
[13]  
GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033
[14]  
Grillot DAM, 1997, J IMMUNOL, V158, P4750
[15]   BCL-2 family members and the mitochondria in apoptosis [J].
Gross, A ;
McDonnell, JM ;
Korsmeyer, SJ .
GENES & DEVELOPMENT, 1999, 13 (15) :1899-1911
[16]   Distinct signaling from stem cell factor and erythropoietin in HCD57 cells [J].
JacobsHelber, SM ;
Penta, K ;
Sun, ZH ;
Lawson, A ;
Sawyer, ST .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (11) :6850-6853
[17]   Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors [J].
Karni, R ;
Jove, R ;
Levitzki, A .
ONCOGENE, 1999, 18 (33) :4654-4662
[18]   MCL1, A GENE EXPRESSED IN PROGRAMMED MYELOID CELL-DIFFERENTIATION, HAS SEQUENCE SIMILARITY TO BCL2 [J].
KOZOPAS, KM ;
YANG, T ;
BUCHAN, HL ;
ZHOU, P ;
CRAIG, RW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3516-3520
[19]  
KRAJEWSKI S, 1994, CANCER RES, V54, P5501
[20]   Identification of a novel human BCL-X promoter and exon [J].
MacCarthy-Morrogh, L ;
Wood, L ;
Brimmell, M ;
Johnson, PWM ;
Packham, G .
ONCOGENE, 2000, 19 (48) :5534-5538